Alpha-antitrypsin(PPL Therapeutics Plc)

▎药明康德内容团队编辑本期看点1. 新一代高选择性CDK9小分子抑制剂SLS009用于复发/难治性（r/r）淋巴瘤患者的临床研究结果积极，96%的患者在最后一次评估时存活，获得临床缓解的患者的肿瘤负荷减少达62%。2. 一种基于人类巨细胞病毒（HCMV）的在研皮下注射人类免疫缺陷病毒（HIV）T细胞疫苗VIR-1388的1期临床试验于近期完成了首例患者给药。3. 新型吸入式基因疗法KB408的IND申请获FDA批准，用于治疗α1-抗胰蛋白酶缺乏症（AATD）。药明康德内容团队整理SLS009（GFH009）：公布1期临床试验数据 SELLAS Life Sciences公布了其获独家授权的新一代高选择性CDK9小分子抑制剂SLS009在1期临床试验的r/r淋巴瘤患者队列中的积极顶线结果。临床前实验数据显示，SLS009对CDK9蛋白的选择性抑制效力超过其它CDK亚型100倍以上。此次试验共有52例r/r淋巴瘤患者入组，96%的患者在最后一次评估时存活，表明生存获益显著。在34名可评估的患者中，有5人（14.7%）获得了临床缓解，肿瘤负荷减少达62%，另有7名（20.6%）患者实现疾病稳定（SD），总体疾病控制率为35.3%。其中，外周T细胞淋巴瘤患者的临床缓解率为36.4%（4/11）。在每周给药一次的治疗方案中，100%的患者观察到生物标志物MCL1和/或MYC呈剂量依赖性下降。安全性方面，在任何剂量水平下均未出现脱靶安全性问题。VIR-1388：1期临床试验完成首例患者给药 VIR-1388是Vir Biotechnology公司开发的一种基于HCMV的在研皮下注射HIV T细胞疫苗。与之前的在研HIV疫苗不同，VIR-1388旨在诱导大量T细胞识别HIV蛋白，从而预防HIV感染。HCMV载体是一种弱化版的病毒，旨在将HIV疫苗成分传递给免疫系统，而不会导致受试者患病。几个世纪以来，HCMV一直存在于全球大部分人口中。大多数HCMV感染者没有任何症状，也不知道自己感染了这种病毒。HCMV在人体内终生可被检测到，这表明它们有可能输送并安全地帮助人体长期保留艾滋病疫苗成分，从而有望克服在使用寿命较短的疫苗载体时观察到的免疫反应下降问题。目前，VIR-1388正处于1期临床试验中接受安全性、反应原性和免疫原性的评估。KB408：IND申请获得FDA许可 KB408是Krystal Biotech公司以存在复制缺陷、失去了整合基因组能力的1型单纯疱疹病毒（HSV-1）作为载体开发的新型吸入（雾化）制剂，旨在递送编码人α-1抗胰蛋白酶的SERPINA1转基因的两个全长拷贝，用于治疗AATD。近期，KB408的IND申请获得了FDA的许可，该公司计划在2024年第1季度开展1期临床试验。此前，FDA曾授予KB408孤儿药资格，用于治疗AATD。RGLS8429：公布1b期临床试验数据Regulus Therapeutics公司公布了其开发的新型下一代寡核苷酸疗法RGLS8429用于治疗常染色体显性多囊肾病（ADPKD）的1b期临床试验数据。常染色体显性多囊肾病是由PKD1或PKD2基因突变引起的，也是最常见的人类单基因疾病之一，同时是终末期肾病的主要原因。RGLS8429旨在抑制miR-17并优先靶向肾脏，在临床前研究中已被证明能够明显改善肾脏功能、大小和其他疾病严重程度指标，并具有优越的药理学特征。此前，该公司已公布1期单次递增剂量临床试验的结果，结果显示，RGLS8429具有良好的安全性、耐受性和药代动力学（PK）特征。此次公布的结果显示，患者对RGLS8429的耐受性良好，未发现任何安全性问题。经RGLS8429治疗后，与疾病相关的尿液生物标志物尿多囊蛋白1（PC1）有统计学意义的显著增加，并且尿多囊蛋白（PC1和PC2）在ADPKD患者中显示出预期的药代动力学/药效学（PK/PD）关联性。Briquilimab：公布1b期临床试验的新数据Jasper Therapeutics公布了其c-KIT（CD117）单克隆抗体briquilimab作为治疗范可尼贫血（Fanconi Anemia）预处理剂的的积极早期临床结果。结果显示，所有接受briquilimab治疗的患者（3例）均实现了完全供体植入和全血细胞计数恢复。此外，briquilimab的耐受性良好，无任何并发症。PLG0206：公布1b期临床试验的新数据Peptilogics公司公布了其在研广谱、抗菌和抗生物膜肽治疗药物PLG0206用于治疗假体周围感染（PJI）的1b期临床试验的新数据。PLG0206通过独特的作用机制靶向并破坏细菌膜，可直接作用于难以被常规抗生素清除的细菌病原体。在体外和非临床动物研究中，PLG0206表现出卓越的广谱、高效杀菌活性，对包括世界卫生组织和疾病预防控制中心认定的具有重要、紧急或高优先级的各种病原体均有效，无论其耐药性表型如何。PLG0206已被美国FDA授予用于治疗PJI的孤儿药资格，并获得了快速通道资格。此次公布的结果显示，PLG0206在PJI患者中的应用显示出良好的安全性和有效性迹象，高、低剂量组患者均未报告与治疗相关的严重不良事件。此外，接受PLG0206的患者在清创术后、抗生素和植入物保留（DAIR）手术后180天时的感染复发率为7%（1/14），与此前其它研究中报告的类似群体在术后180天时的感染复发率（45%）相比显著下降（p=0.029）。GM-1020：完成1期临床试验Gilgamesh Pharmaceuticals公司宣布其新型非竞争性小分子NMDA通道阻滞剂GM-1020完成了1期单剂量递增和多剂量递增试验。这种新一代疗法旨在改变抑郁症、双相情感障碍、强迫症和其他使人衰弱的精神疾病的治疗格局。这种开创性的疗法是在现有氯胺酮疗法的基础上发展起来的，有望成为一种方便、耐受性良好的家庭治疗选择。此次公布的结果显示，该候选疗法的口服剂量耐受性良好，未发现严重不良反应，并通过脑电图确认了靶点作用。LP-284：IND申请获得FDA许可Lantern Pharma近日宣布，美国FDA已批准其在研新型小分子候选疗法LP-284的IND申请。LP-284是Lantern利用其专有的人工智能和机器学习平台RADR加速和重点开发的具有合成致死作用机制的小分子疗法，可优先对DNA损伤修复通路中携带突变的癌细胞造成损伤。该疗法拟用于治疗复发或难治性非霍奇金淋巴瘤（NHL），包括套细胞淋巴瘤（MCL）、双重打击淋巴瘤（DHL），以及其他高级别B细胞淋巴瘤（HGBL）。Lantern预计将于2023年第4季度开始招募LP-284首次人体1期试验的患者。LPX-TI641：IND申请获得FDA许可LPX-TI641是LAPIX Therapeutics公司开发的一种在研口服生物可利用的小分子T细胞免疫球蛋白和含粘蛋白结构域蛋白（TIM）3/4受体激动剂，正在开发用于治疗神经-自身免疫适应症（如多发性硬化），并打算扩展到类风湿性关节炎和其他自身免疫性疾病。TIM家族受体在自身免疫中发挥着重要作用。LPX-TI641的主要药理作用是上调Foxp3+/DC4+ T细胞（T-regs）和Tim1+/CD25+/CD19+（调节性B细胞，B-regs），以及抑制/下调Th17。LPX-TI64的药理学综合作用是在不影响先天性免疫系统的情况下，让适应性免疫系统重建自我耐受性（Treg/Th17平衡和B-regs）。研究人员在多个多发性硬化动物模型中评估了LPX-TI641与标准疗法的疗效，这些模型显示，LPX-TI641在诱导/维持治疗上具有良好的疗效，模拟了目前多发性硬化的临床治疗模式，且不会诱发中性粒细胞减少症或淋巴细胞减少症。LPX-TI641用于治疗多发性硬化的IND申请已获得FDA批准，预计将于2023年第4季度开始给药。CF-370：向FDA提交IND申请CF-370是ContraFect公司开发的一种工程化的溶素候选疗法，对铜绿假单胞菌具有强活性。该公司官网资料显示，CF-370是首个能穿透铜绿假单胞菌外膜并在人体血清中发挥强效活性的溶素。此外，CF-370还表现出了溶素类药物的体外特征，包括快速而有效的杀菌活性、与多种标准治疗药物的协同作用以及在临床前研究中能够摧毁生物膜。在兔肺炎模型中，CF-370具有良好的耐受性，并能提高动物的存活率。接受CF-370治疗动物的存活率为100%，而接受对照药物治疗动物的存活率仅为40%。此外，CF-370与美罗培南具有协同作用，与单独使用这两种药物相比，模型动物的平均肺部细菌计数显著减少。ContraFect公司已于近期向FDA递交了CF-370的IND申请，拟用于治疗医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎。大家都在看药明康德为全球生物医药行业提供一体化、端到端的新药研发和生产服务，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。如您有相关业务需求，欢迎点击下方图片填写具体信息。▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料（可上下滑动查看）[1] Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort. Retrieved September 18, 2023, from https://www.globenewswire.com/news-release/2023/09/15/2743899/0/en/Harpoon-Therapeutics-Announces-First-Patients-with-Small-Cell-Lung-Cancer-Dosed-in-HPN328-Combination-Cohort.html#:~:text=SOUTH%20SAN%20FRANCISCO%2C%20Calif.%2C%20Sept.%2015%2C%202023%20%28GLOBE,TriTAC%20%C2%AE%2C%20in%20combination%20with%20atezolizumab%20%28Tecentriq%20%C2%AE%29.[2] Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas. Retrieved September 18, 2023, from https://www.businesswire.com/news/home/20230918509354/en[3] LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis. Retrieved September 19, 2023, from https://www.globenewswire.com/news-release/2023/09/18/2744820/0/en/LAPIX-Therapeutics-Inc-Announces-FDA-Clearance-of-IND-Application-for-its-Treg-expanding-Tim3-4-Agonist-LPX-TI641-to-Treat-Multiple-Sclerosis.html[4] Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor. Retrieved September 19, 2023, from https://www.globenewswire.com/news-release/2023/09/18/2744629/37216/en/Aclaris-Therapeutics-Announces-Positive-Results-from-Phase-1-Multiple-Ascending-Dose-Trial-of-ATI-2138-an-Investigational-Oral-Covalent-ITK-JAK3-Inhibitor.html[5] ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370. Retrieved September 19, 2023, from https://www.globenewswire.com/news-release/2023/09/18/2744662/0/en/ContraFect-Announces-Submission-of-IND-Application-to-the-FDA-for-its-Development-Candidate-CF-370.html[6] FSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well Tolerated. Retrieved September 19, 2023, from https://www.accesswire.com/784933/fsd-pharma-announces-interim-results-from-first-in-human-clinical-trial-of-lucid-ms-lucid-21-302-for-multiple-sclerosis-the-report-shows-compound-to-be-safe-and-well-tolerated[7] LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer. Retrieved September 19, 2023, from http://www.businesswire.com/news/home/20230918673241/en[8] Peptilogics Reports Positive 180-Day Top-Line Interim Data From Phase 1B Trial of PLG0206 in Patients With Periprosthetic Joint Infection (PJI) . Retrieved September 20, 2023, from https://www.businesswire.com/news/home/20230919307081/en[9] Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor. Retrieved September 20, 2023, from https://www.globenewswire.com/news-release/2023/09/19/2745462/0/en/Revolution-Medicines-Doses-First-Patient-in-Phase-1-1b-Clinical-Trial-of-RMC-9805-an-Oral-Covalent-Mutant-Selective-KRASG12D-ON-Inhibitor.html[10] Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease. Retrieved September 20, 2023, from https://www.globenewswire.com/news-release/2023/09/19/2745619/0/en/Cerevance-Doses-First-Subject-in-Phase-1-Clinical-Study-of-CVN293-a-Selective-Inhibitor-of-KCNK13-Designed-to-Selectively-Modulate-Neuroinflammation-for-the-Treatment-of-ALS-and-Al.html[11] ImmPACT Bio Doses First Patient in Phase 1/2 Trial Evaluating IMPT-314, a Bispecific CD19/CD20 CAR T-cell Therapy for the Treatment of Aggressive B-cell Lymphoma. Retrieved September 20, 2023, from https://www.prnewswire.com/news-releases/immpact-bio-doses-first-patient-in-phase-12-trial-evaluating-impt-314-a-bispecific-cd19cd20-car-t-cell-therapy-for-the-treatment-of-aggressive-b-cell-lymphoma-301931229.html[12] Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa. Retrieved September 20, 2023, from https://api.newsfilecorp.com/redirect/pEoA5UjwPb[13] Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Retrieved September 21, 2023, from https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-positive-topline-data-from-the-first-cohort-of-patients-in-its-phase-1b-multiple-ascending-dose-mad-clinical-trial-of-rgls8429-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adp-301932766.html[14] Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ. Retrieved September 21, 2023, from https://www.globenewswire.com/news-release/2023/09/20/2746463/0/en/Protara-Therapeutics-Announces-Dosing-of-First-Patient-in-Phase-1b-2-ADVANCED-2-Trial-of-TARA-002-in-NMIBC-Patients-with-High-Grade-Carcinoma-in-Situ.html[15] Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV. Retrieved September 21, 2023, from https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-first-participant-dosed-new-phase-1[16] Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020. Retrieved September 21, 2023, from https://www.prnewswire.com/news-releases/gilgamesh-pharmaceuticals-successfully-completes-phase-1-sadmad-clinical-trials-of-gm-1020-301934271.html[17] Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) application for VNT-101, a novel direct-acting antiviral against Influenza A virus. Retrieved September 21, 2023, from https://www.prnewswire.com/news-releases/via-nova-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-vnt-101-a-novel-direct-acting-antiviral-against-influenza-a-virus-301934192.html[18] SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met. Retrieved September 22, 2023, from https://www.globenewswire.com/news-release/2023/09/21/2747276/0/en/SELLAS-Announces-Positive-Topline-Data-in-Lymphoma-Cohort-from-SLS009-Phase-1-Dose-Escalation-Trial-Supporting-Advancement-to-Phase-2-Clinical-Study-Primary-and-Secondary-Endpoints.html[19] Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific Symposium. Retrieved September 22, 2023, from https://www.globenewswire.com/en/news-release/2023/09/21/2747221/0/en/Jasper-Therapeutics-to-Present-New-Positive-Data-on-Briquilimab-Conditioning-in-Patients-with-Fanconi-Anemia-at-the-2023-Fanconi-Anemia-Research-Fund-Scientific-Symposium.html[20] Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency. Retrieved September 22, 2023, from https://www.globenewswire.com/news-release/2023/9/21/2747316/0/en/Krystal-Biotech-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-KB408-for-the-Treatment-of-Type-1-Alpha-1-Antitrypsin-Deficiency.html 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

SAN DIEGO, Sept. 19, 2023 /PRNewswire/ -- Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that Chiesi Farmaceutici S.p.A ("Chiesi") declined to exercise its option for the ex-North American rights to develop and commercialize INBRX-101 for the treatment of patients with emphysema due to Alpha-1 Antitrypsin Deficiency ("AATD"). Inhibrx's delivery of the European Medicines Agency ("EMA") scientific advice to Chiesi triggered a 60-day option period to obtain an exclusive license to develop and commercialize INBRX-101 for the treatment of patients with AATD outside of the United States and Canada. On September 18, 2023, Chiesi notified Inhibrx it was declining this option. "We believe Inhibrx is now optimally positioned with full global rights to INBRX-101. This enables broader strategic optionality, including potentially launching Graft versus Host Disease ("GvHD") as a first indication in Europe and Japan. The number of allogeneic transplants in Europe and Japan are double that of the United States and since GvHD therapies have a clear reimbursement path in these markets, we see this as a significant opportunity to help more patients desperately in need," said Mark Lappe, CEO of Inhibrx. About INBRX-101 and AATD INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein designed to safely achieve and maintain levels of alpha-1 antitrypsin ("AAT"), found in healthy individuals with the potential for a less frequent dosing interval compared to the weekly infusion interval of the currently available plasma-derived AAT therapies. AATD is an inherited orphan disease affecting an estimated 100,000 patients in the United States and is characterized by deficient levels of the AAT protein, which causes loss of lung tissue and function and decreased life expectancy. Augmentation therapy with plasma-derived AAT is the current standard of care but does not maintain patients in the normal AAT range, requires frequent and inconvenient once-weekly IV dosing, and relies on plasma collection practices that might not be sustainable. Inhibrx is currently conducting the ElevAATe trial, which is designed as a randomized, controlled, double-blind, head-to-head superiority study examining INBRX-101 against plasma-derived AAT. The primary endpoint of the trial is the mean change in the average functional AAT ("fAAT") concentration as measured by anti-neutrophil elastase capacity from baseline to average serum trough fAAT concentration at steady state (Ctrough,ss). Secondary endpoints are a comparison of the mean change in fAAT concentration from baseline to fAAT average concentration at steady state (Cavg,ss), and the percentage of days with fAAT above the lower limit of the normal range during steady-state dosing. The initial read-out from the ElevAATe trial is expected to occur in late 2024 and the Company plans to meet with the FDA following completion of that study. About INBRX-101 and GvHD Hematopoietic stem cell transplants ("HSCTs") provide an often-curative option for many patients with hematological and oncological conditions, with multiple myeloma, Non-Hodgkin lymphoma, and acute myelogenous leukemia being the most common diseases requiring an HSCT treatment. GvHD is a significant problem that can occur post-surgery, usually after an allogeneic transplant, where the cells donated during the transplant see the recipient's body as foreign and attack the body. Strong clinical data and established guidelines for the use of AAT therapy already exist for acute cases of GvHD. Current clinical data for plasma-derived AAT therapies for the treatment of GvHD show promising response rates and favorable safety profiles over approved therapies, but half-life of the therapies is short and therefore requires dosing every two to four days. Based on the observed favorable safety profile of INBRX-101 to date coupled with its extended half-life, we believe INBRX-101 has the potential for greater efficacy due to the ability to dose at higher levels less frequently, while also eliminating the pathogenic risk from plasma-derived products, which can be life threatening in immunocompromised patients susceptible to infection. Inhibrx plans to initiate studies for both acute and chronic GvHD during the first half of 2024. About Inhibrx, Inc. Inhibrx is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. For more information, please visit . Forward-Looking Statements Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: Inhibrx's and its investigators' judgments and beliefs regarding the observed safety and efficacy to date of its therapeutic candidate, INBRX-101, discussions with and beliefs regarding future action by the FDA, including any potential accelerated regulatory pathway, whether a trial is registration-enabling, evaluations and observations of FDA discussions, statements and beliefs regarding the current standard of care for AAT and GvHD and the sustainability of current plasma collection practices, potential payor reimbursement, future clinical development, application and dosage of INBRX-101 and any presumption of or implied presumption of positive results from pre-clinical studies, Phase 1 clinical trials, or later clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, if approved; its ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection it is able to establish and maintain for intellectual property rights covering its therapeutic candidates; its ability to enter into strategic partnerships and the potential benefits of these partnerships; its estimates regarding expenses, capital requirements and needs for additional financing and financial performance; and other risks described from time to time in Inhibrx's filings with the U.S. Securities and Exchange Commission (the SEC), including under the heading "Risk Factors" in Inhibrx's Annual Report on Form 10-K filed with the SEC on March 6, 2023 and subsequently filed reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release contains estimates and other statistical data made by independent parties and by Inhibrx. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Investor and Media Contact: Kelly Deck, CFO [email protected] 858-795-4260 SOURCE Inhibrx Inc.